SG11201906157YA - Dosing regimens and dosage forms for targeted tgf-b inhibition - Google Patents

Dosing regimens and dosage forms for targeted tgf-b inhibition

Info

Publication number
SG11201906157YA
SG11201906157YA SG11201906157YA SG11201906157YA SG11201906157YA SG 11201906157Y A SG11201906157Y A SG 11201906157YA SG 11201906157Y A SG11201906157Y A SG 11201906157YA SG 11201906157Y A SG11201906157Y A SG 11201906157YA SG 11201906157Y A SG11201906157Y A SG 11201906157YA
Authority
SG
Singapore
Prior art keywords
international
dosage forms
pct
dosing regimens
inhibition
Prior art date
Application number
SG11201906157YA
Other languages
English (en)
Inventor
Isabelle Dussault
Bawab Samer El
Yulia Vugmeyster
Akash Khandelwal
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201906157YA publication Critical patent/SG11201906157YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10—Bag-type containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Endoscopes (AREA)
SG11201906157YA 2017-01-07 2018-01-05 Dosing regimens and dosage forms for targeted tgf-b inhibition SG11201906157YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762443698P 2017-01-07 2017-01-07
US201762581978P 2017-11-06 2017-11-06
PCT/US2018/012604 WO2018129331A1 (en) 2017-01-07 2018-01-05 Dosing regimens and dosage forms for targeted tgf-b inhibition

Publications (1)

Publication Number Publication Date
SG11201906157YA true SG11201906157YA (en) 2019-08-27

Family

ID=62791283

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906157YA SG11201906157YA (en) 2017-01-07 2018-01-05 Dosing regimens and dosage forms for targeted tgf-b inhibition

Country Status (15)

Country Link
US (1) US20190330375A1 (enExample)
EP (1) EP3565599A4 (enExample)
JP (1) JP2020514290A (enExample)
KR (1) KR20190102059A (enExample)
CN (1) CN110198738A (enExample)
AU (1) AU2018205233A1 (enExample)
BR (1) BR112019013924A2 (enExample)
CA (1) CA3048646A1 (enExample)
CL (1) CL2019001871A1 (enExample)
IL (1) IL267856A (enExample)
MX (1) MX2019008001A (enExample)
PH (1) PH12019501574A1 (enExample)
RU (1) RU2019124875A (enExample)
SG (1) SG11201906157YA (enExample)
WO (1) WO2018129331A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
LT3628049T (lt) 2017-05-04 2023-08-25 Acceleron Pharma Inc. Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
JP2021528399A (ja) * 2018-06-22 2021-10-21 メルク パテント ゲーエムベーハー 胆道癌を治療する際に使用するための標的ＴＧＦ−β阻害のための投薬計画
JP2021529777A (ja) * 2018-07-02 2021-11-04 メルク パテント ゲーエムベーハー 進行非小細胞肺癌の治療のための標的ＴＧＦ−β阻害による組み合わせ療法
CN112672753B (zh) 2018-07-09 2025-07-08 普瑞赛格恩公司 融合构建体及其使用方法
CA3118415A1 (en) * 2018-11-09 2020-05-14 Jiangsu Hengrui Medicine Co., Ltd. Tgf-.beta. receptor fusion protein pharmaceutical composition and use thereof
SG11202108099WA (en) 2019-01-30 2021-08-30 Scholar Rock Inc LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ AND USES THEREOF
KR102815892B1 (ko) 2019-06-10 2025-06-04 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 PDL1 및 TGFβ에 대한 2기능성 융합 단백질 및 이의 용도
CN112574314A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 一种融合蛋白及其应用
WO2021081321A1 (en) * 2019-10-24 2021-04-29 Amgen Inc. Systems and approaches for drug delivery
US20230044248A1 (en) * 2019-11-01 2023-02-09 Ares Trading S.A. COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER
US20230340122A1 (en) * 2019-11-05 2023-10-26 Glaxosmithkline Intellectual Property (No. 4) Ltd. Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
US12527839B2 (en) 2019-11-05 2026-01-20 Acceleron Pharma Inc. Treatments for systemic sclerosis
CA3158047A1 (en) * 2019-12-11 2021-06-17 Yunying CHEN Bi-functional antibody against pd-l1 and tgf?
WO2021123432A1 (en) * 2019-12-20 2021-06-24 Ares Trading S.A. Igg:tgfbetarii fusion protein composition
CN111118064B (zh) * 2019-12-24 2022-10-25 华南理工大学 一种精子生成障碍动物模型及其制备方法与应用
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
CA3166328A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
CN115135675A (zh) * 2020-02-18 2022-09-30 南京金斯瑞生物科技有限公司 融合蛋白及其用途
CN115175942B (zh) * 2020-02-25 2025-05-30 上海药明生物技术有限公司 一种双功能融合蛋白及其用途
US12194094B2 (en) 2020-07-10 2025-01-14 Precigen, Inc. Fusion constructs and methods of using thereof
CN116323657B (zh) * 2020-09-24 2023-12-08 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
EP4306131A4 (en) 2021-03-08 2025-06-18 Nanjing GenScript Biotech Co., Ltd. ANTIBODY DELIVERY USING A DUAL VIRAL VECTOR SYSTEM
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4351640A1 (en) * 2021-06-07 2024-04-17 Ares Trading S.A. Combination treatment of cancer
MX2024006018A (es) * 2021-11-19 2024-07-29 Merus Nv Unidades de union multiespecificas que comprenden los dominios de union a pd-1 y tgf-brii.
EP4676954A1 (en) 2023-03-07 2026-01-14 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5785682A (en) * 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
US8993524B2 (en) * 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20130110045A1 (en) * 2011-10-31 2013-05-02 Ming-Yuan Wu Single use intravenous therapy administering device with needle safety covers
PL3489254T3 (pl) * 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
HRP20210977T1 (hr) * 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
AU2015380397B2 (en) * 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
ES2820768T3 (es) * 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
DK3294770T4 (da) * 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer

Also Published As

Publication number Publication date
RU2019124875A3 (enExample) 2021-07-08
KR20190102059A (ko) 2019-09-02
RU2019124875A (ru) 2021-02-08
EP3565599A4 (en) 2020-07-01
PH12019501574A1 (en) 2019-11-04
CA3048646A1 (en) 2018-07-12
EP3565599A1 (en) 2019-11-13
JP2020514290A (ja) 2020-05-21
MX2019008001A (es) 2019-09-09
CL2019001871A1 (es) 2019-12-13
US20190330375A1 (en) 2019-10-31
WO2018129331A1 (en) 2018-07-12
CN110198738A (zh) 2019-09-03
AU2018205233A1 (en) 2019-07-11
IL267856A (en) 2019-09-26
BR112019013924A2 (pt) 2020-02-11

Similar Documents

Publication Publication Date Title
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201909825VA (en) Hsp90 inhibitor oral formulations and related methods
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201805072PA (en) Nicotine powder delivery system
SG11201810423XA (en) Pd-1 / pd-l1 inhibitors for cancer treatment
SG11201907023UA (en) Method of reducing neutropenia
SG11201901126UA (en) Combination therapy for cancer
SG11201903155XA (en) Pharmaceutical compounds
SG11201810034XA (en) ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201804934PA (en) Novel Compounds
SG11201809630RA (en) Nicotine particles
SG11201805204WA (en) Nicotine particle capsule
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201809594WA (en) Nicotine particles and compositions
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201806251WA (en) Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900361RA (en) Methods of treating prostate cancer